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Many viral pathogens encode the motor proteins named RNA helicases which display various functions in genome replication.
General strategies to design specific and selective drugs targeting helicase for the treatment of viral infections could act via one or
more of the following mechanisms: inhibition of the NTPase activity, by interferences with ATP binding and therefore by limiting
the energy required for the unwinding and translocation, or by allosteric mechanism and therefore by stabilizing the conformation
of the enzyme in low helicase activity state; inhibition of nucleic acids binding to the helicase; inhibition of coupling of ATP
hydrolysis to unwinding; inhibition of unwinding by sterically blocking helicase translocation. Recently, by in vitro screening
studies, it has been reported that several benzotriazole, imidazole, imidazodiazepine, phenothiazine, quinoline, anthracycline,
triphenylmethane, tropolone, pyrrole, acridone, small peptide, and Bananin derivatives are endowed with helicase inhibition of
pathogen viruses belonging to Flaviviridae, Coronaviridae, and Picornaviridae families.
1. Introduction
To convert a closed double-stranded DNA or RNA helix into
two open single strands, so that other protein machinery can
manipulate the polynucleotides, the cells require helicases.
They are motor proteins that use energy derived from ATP
hydrolysis [1–4]. Several DNA and RNA helicases have been
isolated from all kingdoms of life, from virus to man [5–
8]. Detailed structural information, biological mechanisms,
and clear outlook on inhibitors of therapeutic relevance as
antiviral agents are recently provided by Xi et al. [9], Kwong
et al. [10], and overall Frick et al. [11, 12].
Several ssRNA+ (positive sense single-stranded RNA)
helicases have been studied in detail including those from
Dengue fever virus (DFV), West Nile virus (WNV), and
Japanese encephalitis virus (JEV). More in general, a recent
article on anti-Flaviviridae chemotherapy has been published
by Ghosh and Basu [13], who expand the original informa-
tion regarding the role of helicases in Flaviviridae previously
reported by Borowski [14].
This enzyme is a promising target to develop new
therapies and preventative agents, since ssRNA+ viruses
belonging to families like Flaviviridae, Coronaviridae, and
Picornaviridae cause clinically significant diseases both in
humans and animals, determining life lost, economical loss,
and higher productivity costs. Examples are the bovine
viral diarrhea virus (BVDV), a serious welfare problem that
significantly damages the farm business, and the Hepatitis
C virus [HCV], that is now a global public health issue,
being a major cause of human hepatitis [15]. Actually,
with the exception of YFV, no vaccine exists against the
various Flaviviridae members therefore, new therapies and
preventative agents are strongly needed.
Viruses belonging to Picornaviridae family cause a variety
of illnesses, including meningitis, cold, heart infection,
conjunctivitis, and hepatitis [16]. This family includes nine
genera, some of which comprise major human pathogens,
namely, Enterovirus (including Poliovirus, Coxsackievirus,
Echovirus), Rhinovirus (approximately 105 serotypes), and
Hepatovirus (Hepatitis A virus). At present, no specific
antiviral therapy is available for the treatment of Picornaviri-
dae infections.
Finally, Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV), an enveloped virus, has recently infected
thousand of humans, with about 800 deaths, and no vaccine
or specific antiviral therapy is known against this virus.











































Figure 1: Mechanism of helicase-catalyzed ATP hydrolysis. Helicases coordinate an ATP, Mg2+ and a water molecule using a conserved Lys
and Asp in the Walker A and B motifs on one RecA-like domain and an Arg on an adjacent RecA-like domain. A Glu likely acts as a catalytic
base by accepting a proton from the attacking water molecule [11].
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Figure 2: Simplified representation of structure of Hepacivirus and Flaviviruses polyprotein.
No retroviruses or ssRNA− viruses have been reported
to encode the synthesis of a helicase; they might simply
utilize helicases encoded by the host cell instead of their
own proteins, as recently shown for HIV replication, which
requires the humanDDX3DEAD-box RNA helicase [17, 18].
In ssRNA+ viruses, the RNA helicases are implicated in
several functions including RNA genome replication, ribo-
some biogenesis, messengers RNA transcription, pre-mRNA
splicing, RNA maturation, RNA export and degradation, as
well as RNA translation [19, 20].
Basing on certain signature motifs in the amino acid
sequence, Gorbalenya and Koonin have shown that all
helicases can be classified in several genetic families [21].
All but two of the helicase families can be grouped into
one of three larger “superfamilies,” designed as superfamily
1 (SF1), superfamily 2 (SF2) [22], and superfamily 3 (SF3)
[23].
Of the remaining 2 families, one is similar to the DnaB
helicase of E.coli [5] and the other resembles the E.coli Rho
helicase that is used in transcriptional termination [24]. Only
the DnaB-like family, sometimes called family 4 (F4) or
superfamily 4 (SF4), contains viral proteins [25].
All helicases bind NTP using two structurally common
amino acidic sequences named motif I and motif II,
described by Walker et al. [25] and Subramanya et al.
[26]. Motif I (also known as Walker A motif/boxes A) is a
phosphate-binding P-loop that also interact with the ribose,
while motif II (also known as Walker B/boxes B) is a Mg2+
co-factor binding loop. The ATP-binding site of helicase
is completed by an arginine “finger” and a catalytic base,
which accepts a proton from the attacking water molecule.
In related proteins, this catalytic base has been demonstrated
to be a conserved glutamate near theWalker Bmotif [27, 28].
Arginine amino acids often interact with the beta and gamma
phosphates of the bound ATP, stabilizing the transition state
[29, 30], Figure 1.
All helicases can also be classified according to their
movement relative to the nucleic acid strand to which they
are primarily associated or to their quaternary structures.
Thus, a helicase can be classified basing on each of the
three above schemes. For example, the helicase encoded by
HCV (Hepatitis C Virus) is an SF2, nonring, 3′–5′ RNA
helicase. Human papillomavirus helicase is an SF3, ring, 3′–
5′ DNA helicase.











































































Figure 4: Structure of the halogenated benzotriazoles TBBT (4) and DRBT (5).
The functional importance of helicases means that
inhibitors or modulators for these enzymes are potentially
important as therapeutic agents. Over the past decade,
significant progress has been made in the development of
highly selective inhibitors as antiviral and anticancer drugs
for clinical uses. Developing nontoxic helicase inhibitors as
antiviral drugs is considerably more diﬃcult than developing
drugs designed to inhibit other viral enzymes. In fact,
in contrast with proteases and polymerases, the helicases-
dependent reactions are still not fully elucidated. Further-
more, the helicase ATP-binding site is conserved not only
in all the classes of helicases, but also in other proteins
necessary for the cellular lifecycle, such as small GTPases,
kinases, the AAA+ family (ATPases associated with various
cellular activities), and even the mitochondrial ATP synthase
(F1 ATPase). Thus, compounds that inhibit helicases via
their ATP-binding sites could have toxic eﬀects on the host
cells.
2. Viral RNA Helicases As
Antiviral Drug Targets
Many viral pathogens encode RNA helicases which have been
demonstrated essential for viral replication and pathogenesis
[31–33]. Between them are
(i) emerging or re-emerging viruses with pandemic
potential, such as SARS-Cov (Severe Acute Respira-
tory Syndrome-Coronavirus), Dengue, West Nile, and
Japanese encephalitis viruses,

















































































































Figure 6: Synthesis of 4, 5, 6, 7-tetrabromo 1H-benzimidazole.
(ii) viruses that have a stable spread worldwide, such as
HCV (Hepatitis C Virus),
(iii) viruses that do not have a large spread, but can
generate serious health problems because of lack or
limited availability of eﬀective drugs, such as CVB
(Human Coxsackie B Virus).
General strategies to design specific and selective drugs
for the treatment of viral infections targeting helicase could
act via one or more of the following mechanisms:
(1) inhibition of the NTPase activity by interferences
with ATP binding and therefore by limiting the
energy required for the unwinding and translocation,
(2) inhibition of the NTPase activity by allosteric mech-
anism and therefore by stabilizing the conformation
of the enzyme in low helicase activity state,
(3) inhibition of nucleic acids binding to the helicase,
(4) inhibition of coupling of ATP hydrolysis to unwind-
ing,
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Figure 8: Structures of the ring expanded nucleosides 31 and 32.
(5) inhibition of unwinding by sterically blocking heli-
case translocation,
(6) development of small molecule antagonists against
essential protein-protein interactions involving heli-
cases.
Some characteristics of helicase families of pathogen
viruses belonging to Flaviviridae, Coronaviridae, and Picor-
naviridae families are reported in Table 1 [9, 10, 34].
3. Flaviviridae
The Flaviviridae is a large family of related positive-
strand RNA viruses that currently consists of three genera:
Flavivirus, Pestivirus (from the Latin pestis, plague), and
Hepacivirus (from the Greek hepatos, liver). In addition, the
family includes two groups of viruses, GBV-A and GBV-C,
that are currently unassigned to a specific genus and await
formal classification [35]. Within this family are comprised
viruses that cause significant diseases in human and animal
populations. From Flavivirus genus is Dengue virus (DENV)
with its associated dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS), Japanese encephalitis virus
(JEV), West Nile virus (WNV), Yellow Fever virus (YFV),
and tick-borne encephalitis virus (TBEV). The Pestiviruses
are animal pathogens of major economic importance for the
livestock industry, like bovine viral diarrhea virus (BVDV),
border disease virus (BDV) of sheep, and classical swine
fever virus (CSFV). The Hepacivirus genus includes only the
hepatitis C virus (HCV), an important human pathogen.
HCV, identified in 1989 [36], is a major cause of human
hepatitis, globally, and infects about 3% of the world’s
population [37]. Hepacivirus is spread primarily by direct
contact with human blood; hence, the major causes of
infection are use of unscreened blood transfusions and
reuse of needles and syringes that have not been adequately
sterilised. The World Health Organization (WHO) estimates
that over 170million people worldwide are presently infected
with this virus [38]. Most infections become persistent and
about 60% of cases progress towards chronic liver disease,
that can lead to development of cirrhosis, hepatocellular
carcinoma, and liver failure [39, 40].
Pegylated interferon in combination with ribavirin is
used in the clinic for hepatitis due to HCV. Unfortunately,
this therapy requires lengthy periods of administration
and is often associated with severe and adverse events.
Furthermore, this drug has limited eﬃcacy and the sustained
virological response rate is of 40–50% in genotype HCV-
1 infected patients, and of 80% in those infected with
genotypes 2 and 3 [41, 42].























































































(3) DEAE-cellulose chromatography using triethylammonium bicarbonate (TEAB) buﬀer
(4) NaI, acetone
Figure 9: Synthesis of compounds 33 and 34.
Table 1: Viral helicases of same ssRNA+ Viruses (belonging to Flaviviridae, Coronaviridae, and Picornaviridae families) [9, 10, 33].
Family Species Helicase family Helicase name In vitro activity
Flaviviridae
Yellow fever virus SF2 NS3 RNA stimulated NTPase
West Nile virus SF2 NS3 RTPase 3′–5′ helicase
Dengue fever virus SF2 NS3 3′–5′RNA helicase RTPase
Japanese encephalitis virus SF2 NS3 3′–5′RNA helicase
Bovine viral diarrhea virus SF2 NS3 3′–5′RNA helicase
Hepatitis C virus SF2 NS3 3′–5′RNA /DNA helicase
Hepatitis G virus SF2 NS3 3′–5′RNA /DNA helicase
Hepatitis A virus SF3 2C NTPase
Coronaviridae
Human coronavirus 229E SF1 Nsp 13 3′–5′RNA/DNA helicase RTPase
SARS Coronavirus SF1 Nsp 13 3′–5′RNA/DNA helicase RTPase
Picornaviridae
Poliovirus SF3 2C NTPase
Rhinovirus SF3 2C NTPase
This emphasizes that new therapies are clearly needed,
since for the treatment of this infection, and generally for
diseases caused by viruses belonging to the Flaviviridae
family, therapeutic strategies really eﬀective and selective are
not available.
All of the 12 HCV genotypes, which have nucleotide
sequences that diﬀer by as much as 30%, produce a
single polyprotein of about 3,000 amino acids, which is
subsequently processed by viral and host proteases into four
structural proteins and six nonstructural proteins (altogether
10 mature proteins). As summarized in Figure 2, the
structural proteins (S proteins: core, E1, E2, and p7) generate
the viral capsid and envelope proteins and are cleaved by
host-signal peptidases, while the six nonstructural proteins
(NS proteins: NS2, NS3, NS4A, NS4B, NS5A, and NS5B) are
responsible for genome replication and are largely generated
by HCV-encoded protease [43].
HCV Helicase is part of the bi-functional NS3 pro-
tein, carrying three diﬀerent enzymatic activities: helicase,
NTPase, and serine protease activities.
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Figure 11: Chemical structure of 1-(2′-O-Methyl-β-D-ribofuranosyl)imidazo[4,5-d]pyridazine-4, 7(5H, 6H)-dione (HMC-HO4) (60).




















Figure 13: Structure of the calmodulin antagonist trifluoperazine
(62).
NS3 helicase is essential for viral replication, and this
makes it one of the most promising target for the antiviral
therapy.
The known HCV helicase inhibitors can be classified on
the base of their mechanism of action, into the first four
groups of those above cited:
(1) inhibitors of NTPase activity by interference with
NTP binding,
(2) inhibitors of NTPase activity by allosteric mecha-
nism,
(3) competitive inhibitors of RNA binding,
(4) inhibitors of the coupling of NTP hydrolysis at the
unwinding reaction.
3.1. Inhibition of NTPase Activity by Interference with NTP
Binding. The hydrolysis of ATP supplies the energy that
allows the helicase to adopt various nucleotide ligation
states that allosterically cause conformational changes in
the nucleic acid binding site to drive the movement of the
helicase along the length of the nucleic acid chain [19]. So,
competitive NTPase inhibitors may lead to decreased ATPase
activity and therefore to reduction of the unwinding rate.
Consequently, non-(or slowly) hydrolysable ATP-analogs
seemed to be eﬀective tools for inhibiting the helicase activ-
ity, like adenosine-5′γ-thiotriphosphate (ATP-γ-S), which is
used to determine a low level of unwinding of HCV dsRNA
[44, 45]. However, ribavirin 5′-triphosphate (RTP), that
inhibits the HCV NTPase/helicase by a competitive mech-
anism in regard to ATP [46], and ribavirin 5′-diphosphate
(RDP), both reported in Figure 3, even showing IC50 values
in the micromolar range, demonstrates to determine only
a weakly enzymatic inhibition [34]. The same behavior has
been put in evidence for paclitaxel, compound structurally
nonrelated to NTP. This derivative is able to block the NTP-
binding site (IC50 = 22 μM) and to inhibit the ATPase activity
(IC50 = 17 μM) in a competitive way, but is not able to inhibit
the helicase activity at concentration lower than 1mM [14]
The partial unwinding activity mediated by these com-
petitive NTPase inhibitors is common to all members of
the class, and the concentrations needed for the helicase
inhibition usually exceed the IC50 value by 3–5 times. At
these concentrations, the NTPase activity reached 10–35% of
the control [46–48]. The basis for the phenomenon remains
unclear.
On the other hand, most potent benzotriazole helicase
inhibitors were identified during the course of a ran-
dom screening study [49, 50]. In particular, 4, 5, 6, 7-
tetrabromobenzotriazole (TBBT) (4), known as a potent
and highly selective inhibitor of protein kinase 2, and
5,6-dichloro-1-(β-D-ribofuranosyl) benzotriazole (DRBT)
(5) displayed IC50 values of 20 and 1.5 μM, respectively
(Figure 4).
On the contrary, the corresponding imidazole derivative
of DRBT, the 5, 6-dichloro-1-(β-D-ribofuranosyl) benzimi-
dazole (DRBI), against NTPase/helicase of a large number of
members of the Flaviviridae family (HCV, WNV, DENV, and
JEV) resulted to be completely inactive.
To explain this finding, Bretner et al. synthesized and
studied a new series of substituted (alkyl, hydroxy alkyl,
chloro alkyl, ribofuranose) 1H-benzimidazole and 1H-
benzotriazole derivatives shown in Figures 5 and 6 [50, 51].
TBBT (more less DRBT) resulted eﬀective in HCV
subgenomic replicon system in a comparable way to the
inhibition reported in the enzymatic essays, showing a
property that has been detected only for a handful group of
HCV inhibitors [52].
It has been reported that the starting compounds 1H-
benzotriazole (6) and 1H-benzimidazole (17), screened for
their eﬀect against the HCV-helicase, showed
(i) very low activity (IC50 200 μM and 500 μM, respec-
tively) when measured with a DNA substrate,
(ii) no activity when measured either with an RNA
substrate or against the flavivirus enzymes of WNV,
DENV, and JEV (IC50 > 500 μM).
On the contrary, the whole halogenation of 1H-
benzotriazole (6) with bromine atoms, to aﬀord the above
cited 4, caused either a 10-fold or 9-fold more eﬀective
inhibition of the HCV helicase when determined with a DNA
substrate or an RNA substrate, respectively, and of 25-fold in
the case of the JEV enzyme (IC50 20 μM).
The corresponding bromination of 1H-benzimidazole
(17) aﬀorded the derivative (18), which resulted to be less
eﬀective than 4 and 2–2.5 times more potent than parent 17
against HCV helicase.


















































Figure 15: The HCV helicase inhibitors reported by ViroPharma Inc.
When 1- or 2-alkyl benzotriazoles were screened for
their eﬀect on the HCV-helicase activity using the DNA
substrate, the 2-alkylated derivatives (10–12) resulted to be
significantly more potent inhibitors of the enzyme (2- to 7-
times) than the respective 1-alkylated analogues (7–9).
On the other hand, enhancement of the activity was
observed when the aliphatic chain was elongated in both 1-
alkylated benzotriazoles (7–9) and 1-alkylated benzimida-
zoles (19–21) than the respective 2-alkylated analogues. In
the case of the benzimidazole derivatives (19–21), however,
the inhibitory activity was very low and ranged between
250 and 500 μM. Furthermore, the HCV helicase activity of
the alkylated benzimidazoles tested using the RNA substrate,
as well as using other viral NTPase/helicases, displayed no
inhibitory activity.
This behaviour suggests that these inhibitors do not
act by blocking the NTP binding sites of the enzymes
and that occupation of an allosteric nucleoside binding site
should be considered, as previously suggested by Porter
[53].
Furthermore, in this study the authors observed that
replacement of the alkyl side-chain by a substituent endowed
with higher hydrophilicity (hydroxyethyl derivatives 13 and
14 in Figure 5) or with higher hydrophobicity (chloroethyl
derivatives 15 and 16 in Figure 5) dramatically decreases
the activity of the tetrabromobenzotriazoles. Consequently,
it seems that a small hydrophobic alkyl moiety (methyl
or ethyl) at position 2- of the tetrabromobenzotriazole
could play a crucial role in the inhibition of the HCV
NTPase/helicase.
Introduction of a ribofuranosyl ring in both benzotria-
zole and tetrabromobenzotriazole improves the water solu-
bility but leads to a decrease of the inhibitory activity against
HCV and all the enzymes tested. The same substituent in
the position 1 of the 5,6-dichlorobenzotriazole DRBT (5)
was, as above reported, very eﬀective in inhibiting the HCV
10 International Journal of Medicinal Chemistry
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Figure 16: Structures of diamides (67), aminobenzimidazole-derived diamides (68), and two aminophenyl benzimidazole-derived diureas
(69).
and WNV helicases (IC50 1.5 μM and 3.0 μM, respectively)
but ineﬀective against JEV helicase [49]. On the contrary,
replacement of chlorine atoms of the benzotriazole ring with
either bromine atoms or methyl groups (compounds 28–30,
Figure 7) showed lower activity compared to DRBT.
In an extension of this study, an additional class of
nucleoside analogues known as ring-expanded nucleosides
(REN or “fat”) involving 6-aminoimidazo [4,5-e] [1, 3]
diazepine-4,8-dione ring were reported to be active against
the helicase unwinding reaction [54]. A number of RENs,
such as compounds 31 and 32 of Figure 8, displayed IC50
values in the micromolar range. In view of the observed tight
complex between some nucleosides and RNA and/or DNA
substrates of a helicase, the mechanism of REN action might
involve binding to the minor or major groove of the helical
nucleic acid substrate.
The fat nucleosides 31, 32, and TBBT (4) and no-
galamycin (see compound 76) have been recently used
to construct a pharmacophore model for designing new
Japanese encephalitis virus NS3 helicase/NTPase inhibitors,
using a refined structure of this enzyme [55].
On the other hand, the REN 5′-triphosphates, such as
compounds 33 and 34 of Figure 9, did not influence the
unwinding reaction while exerting their inhibitory eﬀect
(IC50 0.55 μM and 1.5 μM, respectively) on the ATPase
activity of the enzyme. As reported in Figure 9, compounds
33 and 34, containing the 5 : 7-fused heterocyclic systems,
imidazo [4,5-e] [1, 3] diazepine and imidazo [4,5-e] [1,
2, 4] triazepine, respectively, were synthesized from the
corresponding nucleosides 36 and 37, employing the Lud-
wig’s procedure [56]. The nucleosides 36 and 37, in turn,
were synthesized by Vorbru¨ggen ribosylation [57–60] of the
respective heterocycles 35 and 38 [61, 62].
Therefore, in exploring the potential anti-Flaviviridae
activity of the ring system contained in 31, the same
authors focused on diﬀerent substituents (alkyl, arylalkyl,
and aromatic groups) at position 6, along with variations
of sugar moieties at position 1 (ribose, 2′-deoxyribose, or
acyclic derivatives) as well as their attachment to the base (α
or β configuration) [63].
The general method for the synthesis of the designed
nucleosides (41–59) was involved, as reported in Figure 10,
the Vorbru¨ggen ribosylation [53, 54] of dimethyl imidazole-
4,5-dicarboxylate (39) [64, 65], followed by condensation of
the resulting imidazole nucleoside (40) with the appropri-
ately substituted guanidine derivatives.
The modulation eﬀect exerted by RENs can result in an
inhibition or activation. In the first case, the mechanism may
involve the interaction of RENs with a DNA or an RNA
substrate through binding to the major or minor groove of
the double-helix. In the case of activation, the mechanism
may involve an allosteric binding site that can be occupied
by nucleoside/nucleotide-type molecules including, but not
limited to RENs. The occupation of this allosteric site on
the enzyme is dependent upon the high level of ATP (NTP)
concentration in the reaction mixture.
RENs obtained with the above procedures were screened
for inhibition of NTPase/helicase of the WNV. One of




























































Z = O, S
Y = CH, Y
220◦C, 4 h













Figure 18: Symmetrical benzimidazolephenylcarboxamide (BIP)2B.
the most promising among these early inhibitors is 1-(2′-
O-methyl-β-D-ribofuranosyl)imidazo[4,5-d]pyridazine-
4,7(5H,6H)-dione (HMC-HO4) (60), Figure 11, which
produces a promising antiviral eﬀect (EC50 = 25–30 μM)
[66]. At all the concentrations of HMC-HO4, ATP hydrolysis
is stimulated, suggesting that the inhibitor somehow
uncouples the ATPase and helicase functions. In that regard,
RENs may represent a starting point for the development of
highly selective inhibitors of WNV NTPase/helicase.
An other recent starting point is represented by triph-
enylmethane derivatives, as reported from Chen et al. [67].
Compound (61) of Figure 12, where the triphenylmethane
moiety is linked to a 2-(3-bromo-4-hydroxyphenyl)propane,
was identified as a good inhibitor that suppresses HCV
12 International Journal of Medicinal Chemistry




















Figure 20: Molecular structure of compound 74.
RNA replication in the HCV replicon cells through both the
inhibition of ATP hydrolysis and the RNA substrate binding
[67].
3.2. Inhibition of NTPase Activity by Allosteric Mechanisms.
The partial inhibition mediated by the competitive NTPase
inhibitors may be avoided by utilizing compounds chem-
ically unrelated to NTP, which reduce the accessibility to
the NTP-binding site in a noncompetitive manner [68]. An
example is the calmodulin antagonist trifluoperazine (62,
Figure 13). Although the molecule is known to interact with
domain 1 of HCV helicase, it is uncertain if inhibition results
from conformational changes or from blockage of the ATP-
binding site [46].
Even some tropolones have been screened as inhibitors
of HCV helicase-catalyzed DNA unwinding. Recently Berna-
towicz et al. have described several derivatives bearing a side
chain that connect the seven-member ring system to some
N-heterocycles.
The most active compound, 3,5,7-tri[(40-methylpiper-
azin-10-yl)methyl]tropolone (63), inhibited RNA replica-
tion by 50% at 46.9 μM (EC50), showing an IC50 = 3.4 μM
and a CC50 > 1000 μM (SI > 21), whereas the most eﬃcient
was 3,5,7-tri[(30-methylpiperidin-10-yl)methyl]tropolone
(64), with an EC50 of 35.6 μM,which unfortunately exhibited
a lower SI (9.8) derived by a CC50 = 348 μM. These tropolone
derivatives, reported in Figure 14, are the first antihelicase
compounds that inhibit HCV replication with the ability to
cause the appearance of resistant mutants, suggesting that
inhibition of replication is the result of inhibition of the
enzyme activity. They also inhibit replication of the HCV
subgenomic replicon in cell cultures [69].
3.3. Competitive Inhibition of RNA Binding. Several polynu-
cleotides displayed inhibitory HCV helicase activity. The
inhibition is believed to result from the competition of the
polynucleotides with DNA or RNA substrates, an eﬀect that
could be mimicked by synthetic macromolecules [46].
With the aim of discovering new anti-HCV agents,
ViroPharma synthesized several benzimidazole derivatives,
two of them (compounds 65 and 66, Figure 15) showing
high activity against HCV helicase [70]. Although the exact
mechanism of 65 and 66 is still not clear, they might
compete with nucleic acids in the manner above mentioned.
In particular, the benzene ring and the NH group could
interact by hydrophobic interaction and hydrogen bound,
respectively.
In the attempt to extend the SAR analysis, some new
dimers containing benzimidazole, benzoxazole, pyridinox-
azole, and benzothiazole rings, attached to symmetrical
linkers, were synthesized by Phoon et al., as summarized
in Figure 16 [70, 71]. Preliminary studies of these com-
pounds showed a significant decrease in potency when
the benzimidazole moiety was replaced by the benzox-
azole or benzothiazole rings (compounds 67). On the
other hand, the aminobenzimidazole-diamides (68) and
aminophenyl benzimidazole-diureas (69) derivatives dis-
played, at 25 μg/mL, 6–13, and 20–28 percent inhibitory
activity, respectively.
Likewise, the linker was also implicated in the inhibitory
activity since replacement of the diamide linkage possessed
by 65 with the diurea linkage (compounds 69) led to
reduced potency. Thus, the SAR data indicate that the
benzimidazole ring, the benzene group at the C2 position of
the benzimidazole moiety, and the nature of the linker are
essential for the activity [70].
The synthesis of these analogues is outlined in Fig-
ure 17. Aminophenols and thiophenols, or the correspond-
ing pyridine derivatives, reacted easily with p-aminobenzoic
acid in the presence of polyphosphoric acid to aﬀord
the corresponding oxazole and thiazole derivatives (72).
Subsequent coupling of 72 and 2-aminobenzoimidazole with
the opportune acid dichlorides furnished the products 67–
69.
Belon et al. recently described how a prototype in the
symmetrical benzimidazolephenyl series, the N1,N4-bis[4-
(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide
(BIP)2B, (69a, derivative of 69 with Y = phenyl, Figure 18),
binds directly the HCV NS3 helicase in the same binding
site for RNA in a competitive manner. Furthermore, they
reported that 69a interacts with NS3 encoded non only by
various HCV genotypes, but even by Dengue virus (DV),
Japanese encephalitis virus (JEV) and, even if less tightly, the
related human helicase [72].
Also small peptides specifically inhibit HCV helicases,
even in cells bearing HCV replicon. Between them, a peptide
expressed in bacteria, composed of 14 amino acids (p14,
RRGRTGRGRRGIYR), demonstrated to be the best enzyme
inhibitor. P14 has the same amino-acidic sequence as that

































Figure 21: Structures of two DNA/RNA intercalators doxorubicin (75) and nogalamycin (76) that have displayed inhibition of the























Figure 22: Structural formula of amidinoanthracycline derivative
77.
surrounding the putative HCV helicase arginine finger and
inhibits the replication of HCV replicon in cells with an
EC50 = 83 μM [73], while reduces the DNA unwinding with
an IC50 of 0.2 μM [74].
A new selective inhibitor of the HCV helicase, QU663
(compound 73 of Figure 19), discovered by Maga and
coworkers, showed a potent and selective inhibition with Ki
of 0.75 μM [75]. The study of the inhibition mechanism has
revealed that QU663 is a specific inhibitor of the strand-
displacement activity, without aﬀecting the ability of NS3
helicase to hydrolyse ATP. QU663 could function as a
competitive inhibitor with respect to nucleic acid substrate
by decreasing the aﬃnity of the enzyme for the substrate.
Molecular docking studies further support this explanation.
Therefore, QU663 inhibits the unwinding activity of NS3 in
a competitive manner with respect to the DNA substrate,
making it a promising candidate for a novel class of anti-
HCV drugs.
Recently, a new rational approach for the design of
selective inhibitors of the HCV NS3 helicase brought the
discovery of a novel HCV helicase inhibitor that potentially
could compete for the nucleic acid binding site, occupying
the NS3/RNA binding cler. In consequence of this de novo
drug design, the predicted (E)-methyl 4-((5-(3-oxobut-1-
enyl)-1H-pyrrole-2-carboxamido)methyl)benzoate (74, Fig-
ure 20) was synthesized and tested in the HCV replicon
system. It inhibits HCV replicons with an EC50 of 9 μM, but
showing a CC50 = 30 μM [76].
3.4. Inhibition of the Unwinding through Intercalation of
Polynucleotide Chain. DNA and RNA intercalating com-
pounds are potential helicase inhibitors by increasing the
energy required for duplex/intercalator complex unwinding
[77–79].
In particular, two anthracycline derivatives, doxorubicin
and nogalamycin (compounds 75 and 76, Figure 21), have
been shown to be eﬀective inhibitors of the unwinding reac-
tion [77]. The limits in their application for the treatment
of chronic viral infections is their high cytotoxicity and weak
penetration into the cell. Thus, if intercalative modulation of
the DNA or RNA substrates is to be considered as a possible
antiviral therapy, less toxic and more selective derivatives
must be identified.
As previously seen, the antibiotic nogalamycin (76), that
interacts with allosteric binding site, has been recently used
to obtain a structure-based pharmacophore model for JEV
NS3 helicase/NTPase [55].























IC50 = 8.9 μM
EC50 = 9 μM
CC50 = 174.8 μM
SI = 19.4
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IC50 = 3.8 μM
EC50 = 10.2 μM
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SI = 40.5
80
IC50 = 110 μM
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IC50 = 8.6 μM
EC50 = 0.98 μM
CC50 > 1000 μM
TI > 1000
Figure 24: Structures of 2-fluoro-5-methoxy-9-oxo-N-(pyridin-3-
yl)- -9, 10-dihydroacridine-4-carboxamide (81).
In the aim to find less toxic compounds, a large group
of amidinoanthracyclines, with decreased acute toxicity and
cardiotoxicity compared to the parent antibiotics, were
screened against HCV helicase. From this studies emerged
one of the most potent and selective inhibitors of helicase
activity described in the literature. The derivative 77, showed
in Figure 22, acts not only via intercalation into the double-
stranded DNA substrate, but also impeding formation of
the active helicase complex via competition with the enzyme
for access to the substrate. Tested in the subgenomic HCV
replicon system, 77 it showed an EC50 of 0.13 μM and a
CC50 = 4.3 μM [80].
An other class of compounds that probably acts via
intercalation into double-stranded nucleic acids with strong
specificity for RNA are the acridone derivatives, but a
direct interaction with the viral NS3 helicase cannot be
excluded. A large group of acridones were tested from
Stankiewicz-Drogon et al. using the direct fluorometric heli-
case activity assay to determine their inhibitory properties
towards the NS3 helicase of HCV. From a preliminary
study, N-(pyridin-4-yl)-amide (78) and N-(pyridin-2-yl)-
amide (79) of acridone-4-carboxylic acid emerged to be
eﬃcient RNA replication inhibitors with a good specificity in
subgenomic replicon system and low cytotoxicity (Figure 23)
[81]. Even the thiazolpiperazinyl acridone derivative 80
demonstrated to act as a potent agent against HCV replicons
(EC50 = 3 μM) and as a selective inhibitor of the HCV
NS3 helicase, albeit with low potency (IC50 = 110 μM)
[82]. Comparing acridone derivatives 78 and 79 with 80,
we can see that the amide bonding formed after the
derivatization of acridone-4-carboxylic acid with amines
seemed to increase aﬃnity and selectivity for the NS3 enzyme
[81].
Finally, with the intent to improve the antiviral activity of
acridones, Stankiewicz-Drogon et al. prepared a new class of
compounds, namely, 5-methoxyacridone-4-carboxylic acids
(MACA). From this group, compound 81 (Figure 24) came
out not only as an eﬃcient inhibitor of the NS3 helicase
in the in vitro assay but also as a potent inhibitor of
HCV replication endowed with low cytotoxicity for human
hepatoma cells [83].













































Figure 25: Molecular formula of Bananin (BAN) (82), Iodobananin (IBN) (83), Vanillinbananin (VBN) (84), Eubananin (EUB) (85).
4. Coronaviridae
An enveloped single-stranded positive-sense RNA (ssRNA+)
virus, SARS coronavirus (SARS-CoV), has been recently
identified as the etiological agent of severe acute respi-
ratory syndrome (SARS) in humans [84–88]. About ten
thousand cases of SARS worldwide, including 800 deaths,
were reported in 2003 (WHO data). Although this initial
global outbreak, SARS appears to has been successfully
contained, but it remains a serious concern because no
vaccine or eﬀective drug treatment is actually available.
Recently, Tanner and coworkers have found that Bananin
and three of their derivatives, Figure 25, function as non-
competitive SARS-CoV helicase inhibitors (with IC50 values
in the micromolar range) at a site diﬀerent from the ATP
and nucleic acid binding site, causing inhibition probably
through an allosteric mechanism [89]. In foetal rhesus
kidney-4cells infected with SARS-Cov, Bananin inhibited
the viral replication (IC50 = 10 μM) with low host cellular
toxicity (CC50 = 390 μM) [89].
Finally, in the last years various molecules have been
detected showing an interesting and promising anti-
Coronaviridae activity. Unfortunately, for many of them,
was not identified a clear molecular target or mechanism of
action. The fact remains that the eventual target could be the
NS3 helicase. With this in mind, we report briefly the new
classes of compounds that have emerged in recent published
works. Among them glycopeptide antibiotics [90], which
seem to interfere with the Coronavirus entry process but do
not exclude an unknown cellular target; pyridine N-oxide
derivatives [91]; plant lectins [92], which most probably
interfere with the glycans on the spike protein during virus
entry and virus release; phenanthroindolizines and phenan-
throquinolizidines [93]; tetrahydroquinoline oxocarbazate
derivatives as inhibitor of human cathepsin L and as entry
blockers [94].
5. Picornaviridae
Picornaviridae family includes 9 genera, 3 of which are
human pathogens: Enterovirus (containing poliovirus,
enterovirus, coxsackievirus, echovirus), Rhinovirus (approx-
imately 105 serotypes), and Hepatovirus (Hepatitis A virus).
At present no specific antiviral therapy is available for the
treatment of Picornaviridae infections. The viruses belong-
ing to this family, all having a single-stranded positive-sense
RNA (ssRNA+) genome, cause a dramatic variety of illnesses,
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Figure 27: Molecular formula of compounds 86h and 87e.
including meningitis, colds, heart infection, conjunctivitis,
and hepatitis.
Recently Carta and coworkers reported the synthesis
and antiviral screening of a series of N-[4-(1H(2H)-
benzotriazol-1(2)-yl)phenyl]alkylcarboxamides (86(1-yl),
87(2-yl) [95] and N,N′-bis-[4-(1H(2H)-benzotriazol-1(2)-
yl)phenyl]alkyldicarboxamides (88(1-yl), 89(2-yl)) [78] (see
Figure 26).
Compounds were evaluated in vitro for cytotoxicity
and antiviral activity against a wide spectrum of ssRNA+
viruses, like Bovine Viral Diarrhea Virus (BVDV), Yellow
Fever Virus (YFV), Coxsakie Virus B (CVB-2), Polio Virus
(Sb-1), and Human Immunodeficiency Virus (HIV-1).
Only CVB-2 and Sb-1 were inhibited by N-[4-(1H(2H)-
benzotriazol-1(2)-yl)phenyl]alkylcarboxamide derivatives.
In particular, two of them emerged for their selectivity:
87e, which was the most active against CVB-2 (EC50 =
10 μM and CC50 > 100 μM) and 86h, which was the
most active against Sb-1 (EC50 = 30 μM and CC50=
90 μM), Figure 27 [95]. N-[4-(1H(2H)-benzotriazol-1(2)-
yl)phenyl]alkylcarboxamides (86a–e,g,h and 87a–g) were
prepared by condensation of the amino derivatives 90, 91
with the appropriate anhydrides 92 under stirring at 100◦C
for 2 h, as shown in Figure 28. The N,N′-bis[4-(1H(2H)-
benzotriazol-1(2)-yl)phenyl]alkyldicarboxamides (88a–d,
g, h and 88a–d89a–g, i–k) were in turn prepared, as
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Comp. R R1 R2
a CH3 H H
b CH2CH3 H H
c CH2CH2CH3 H H
d CH3 CH3 CH3
e CH2CH3 CH3 CH3
f CH2CH2CH3 CH3 CH3
g CH3 CF3 H



























Figure 28: Synthesis of N-[4-1H(2H)-benzotriaol-1(2)-yl)phenyl]alkylcarboxamides (86 and 87).
reported in Figure 29, by condensation of the amines 1(2)-




(89d–f) exhibited good activity against Enteroviruses (EC50
were 7–11 μM against CVB-2 and 19–52 μM against Sb-1)
and the bis-5,6-dichloro-benzotriazol-2-yl derivatives (80i–
k) showed very selective activity against CVB-2 (EC50 =
4–11 μM) resulting to be completely inactive against all the
other viruses screened [96].
N-[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcar-
boxamides (86 and 87) were evaluated in silico against the
3D model of the Sb-1 helicase, as exemplified by compounds
86h (a) and 89f (b) in Figure 30. The portion of the enzyme
containing the binding site interacting with the inhibitors
consists of two loops, part of two β-sheets, and part of three
helices.
It is important to notice that, with respect to the N-
[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcarboxamide
series, all theN,N′-bis[4-(1H(2H)-benzotriazol-1(2)-yl)ph-
enyl]alkyldicarboxamide derivatives bind helicase Sb-1
in a diﬀerent manner, as expected, due to their diﬀerent
shapes and dimensions. This is well quantified by the
value of the solvent accessible volume of this new class of
inhibitors, which on average has almost doubled compared
to that of the previous molecular series (e.g., 1672 A˚3 versus
891 A˚3, resp.). Accordingly, it is impossible for the protein
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Comp. R1 R2 n Comp. R1 R2 n
a H H 2 g CF3
CF3
H 2
b H H 3 h H 2
c H H 4 i Cl 2
d CH3 2 j Cl 3

















































88a–d, g, h 89a–g, i–k
Figure 29: Synthesis of N,N′-bis[4-1H(2H)-benzotriaol-1(2)- yl)phenyl]alkylcarboxamides 88a–d, g, h and 89a–g, i–k.
pocket to host N,N′-bis[4-(1H(2H)-benzotriazol-1(2)-yl)
phenyl]alkyldicarboxamides with the same binding mode,
and the results form the docking study reveal that only one
of the two identical inhibitors moieties can be positioned
well within the binding pocket. However, in correspondence
of the most favored binding mode for the most active
compounds, the formation of a new, small network of H-
bonds between 89f and enzyme was observed. In particular,
the analysis of the trajectories of the MD simulations for the
89f/helicase complex as an example indicates that there is a
constant presence of an H-bond which involves the carbonyl
oxygen atom of the Asn179 side chain and the triazole N(1)
atom of the drug, characterized by an average dynamic
length (ADL) of 3.0 A˚. At the same time, it is possible to
verify the formation of other two H-bond interactions, the
former between the C=O backbone group of Ser221 and the
NH group of the amidic moiety of 89f (ADL = 1.6 A˚), and
the latter between the carbonyl oxygen atom of the C=O
group of the same amidic moiety of 89f and the side chain
hydroxyl group of Ser221 (ADL = 2.6 A˚).
Compounds 89i–k also exhibited selectivity against
Coxsackie B2CVB-2. Unfortunately, homology standard
techniques were not able to produce a reliable 3D model for
the CVB-2 virus helicase, due to very low sequence identities
found during alignment processes.
In the absence of a 3D model for the CVB-2 helicase, the
activity of 89i–k can be explained adopting a 2D alignment
analysis.
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(a)
(b)
Figure 30: Binding of compounds 86h (a) and 89f (b) to the
putative binding site on the surface of Polio (Sb-1) helicase.
The putative binding site proposed by Carta and cowork-
ers for Sb-1 is composed by 30 residues and, according to
their 2D alignment, the binding site for CVB-2 diﬀers for
7 residues only. Among these, Ser296 in Sb-1 is mutated to
Arg237 in CBV-2. Following their analysis, and a preliminary
visual inspection based on the swapping of Ser to Arg in the
Polio helicase, they concluded that this is the most important
residue in the case of compounds 89i–k, featuring chlorine
atoms as substituents. In fact, the positively charged side
chain of Arg237 is placed at an average distance of 3.5 A˚ from
the Cl atoms, thus sensibly resulting is strong electrostatic
interactions between the inhibitor and the protein. These
speculations, which may account in part for the selectivity
of these compounds with respect to CVB-2, clearly await
further confirmation from the simulations performed on the
corresponding protein 3D models.
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